DRGT 29

Drug Profile

DRGT 29

Alternative Names: DRGT-29

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Druggability Technologies
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 09 Dec 2016 Discontinued - Phase-I for Breast cancer (Metastatic disease) in Hungary (PO)
  • 14 Apr 2016 DRGT 29 is available for licensing as of 14 Apr 2016. http://www.drgtco.com
  • 14 Apr 2016 Phase-I clinical trials in Breast cancer (Metastatic disease) in Hungary (PO) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top